Recently, Hu et al. reported encouraging results from a phase 1 clinical trial (NCT04538599) in which 11 patients with refractory/relapse T-cell leukemia/lymphoma and one with CD7 positive acute myeloid leukemia received treatment of genetically modified CD7-targeting allogeneic CAR T cells. The gene discussed is CD7; the disease is T-cell leukemia.